Travere Therapeutics (TVTX) S-3ASR Automatic shelf registration

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” in this Registration Statement (Form S-3) and related Prospectus of Travere Therapeutics, Inc. for the registration of common stock, preferred stock, debt securities and warrants, and to the incorporation by reference therein of our reports dated February 20, 2024, with respect to the consolidated financial statements of Travere Therapeutics, Inc., and the effectiveness of internal control over financial reporting of Travere Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

August 1, 2024